Stem Cell Cartilage Regeneration Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Stem Cell Cartilage Regeneration Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Report Description

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.

Market Dynamics

Growing osteoarthritis incidence among the global population is supporting the adoption of stem cell cartilage regeneration therapy. For instance, according to November 2017, Arthritis Foundation data findings, with the increase in global geriatric population, degenerative disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050.

Furthermore, various government agencies are focusing on policies to enhance adoption of stem cell therapies, which is expected to drive growth of stem cell cartilage regeneration market in the near future. For instance, in December 2016, the 21st Century Cures Act (Cures Act) was signed into law by the U.S. FDA, thereby allowing legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) to patients who are in need of it.

However, high cost of treatment is expected to hamper the stem cell cartilage regeneration market during the forecast period. Moreover, extensive time and expertise required to perform stem cell based therapy leads to increase the cost of this procedure. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivering these technologies.

Key features of the study:

• This report provides in-depth analysis of the stem cell cartilage regeneration market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2018 – 2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global stem cell cartilage regeneration market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global stem cell cartilage regeneration market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stem cell cartilage regeneration market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

• Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• Global Stem Cell Cartilage Regeneration Market, By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• Global Stem Cell Cartilage Regeneration Market, By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Global Stem Cell Cartilage Regeneration Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Africa
• By Country:
• South Africa
• Central Africa
• North Africa
• By Stem Cell Type:
• Hematopoietic Stem Cells (HSCs)
• Pluripotent Stem Cells (iPSC/ESCs)
• Mesenchymal Stem Cells (MSCs)
• By Treatment:
• Microfracture
• Osteochondral Transplant
• Autologous Chondrocyte Implantation
• Stem Cell Injections
• By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Company Profiles
• Theracell Advanced Biotechnology Ltd.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Orthocell Ltd.
• Xintela AB
• CellGenix GmbH
• Merck KGaA
• Osiris Therapeutics, Inc.
• BioTissue SA
• Vericel Corporation

“*” marked represents similar segmentation in other categories in the respective section.